PMSI provides CDD on CLS’s acquisition of Aquila Biomedical

Manchester-based Concept Life Sciences has acquired Aquila Biomedical, a pre-clinical contract research organisation (CRO). Concept is an integrated drug discovery, development and analytical services company.

The acquisition is a pivotal addition to the integrated services Concept provides, supporting customers throughout the drug discovery and development process.

Aquila was formed in 2011 by experts from The University of Edinburgh. Aquila has developed novel technologies to help customers to better understand the cellular and molecular events that occur with compound administration.

PMSI provided commercial due diligence for Concept Life Sciences, evaluating Aquila’s leading position within the rapidly expanding immuno-oncology market.

Michael Fort, Executive Chairman, Concept Life Sciences, commented:

“PMSI’s commercial due diligence work helped get all our stakeholders comfortable with the opportunity that Aquila opened up in areas such as immuno-oncology, and the wider commercial and strategic synergies with the existing Concept Life Sciences business.”

“We are excited to add Aquila to the Concept group. The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering. Both Aquila and Concept have been built around the same value of working closely with customers to tailor services according to the project objectives, and together we will provide high quality, integrated solutions.”

Professor Stephen Anderton, co-founder of Aquila Biomedical and Professor of Therapeutic Immunology at Edinburgh University, added:

“We are delighted to be joining the Concept Life Sciences group at this stage in both companies’ development cycles. Concept’s size, business development network and complementary scientific capacity will make the enhanced service offering attractive to the widest group of international clients, and will significantly accelerate our growth.”